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Abstract
The unique physiology and function of neurons create differences in their cellular physiology,
including their regulation of gene expression. We began several years ago exploring the
relationships between the NFκB transcription factor, neuronal survival, and glutamate receptor
activation in telencephalic neurons. These studies led us to conclude that this population of cells is
nearly incapable of activating the NFκB that is nonetheless expressed at reasonable levels. A subset
of the κB cis elements are instead bound by members of the Sp1 family in neurons. Also surprising
was our discovery that Sp1 itself, typically described as ubiquitous, is severely restricted in
expression within forebrain neurons; Sp4 seems to be substituted during neuronal differentiation.
These findings and their implications for neuronal differentiation – as well as potential
dedifferentiation during degenerative processes – are discussed here.
NFκB induction pathways
NFκB consists of two subunits of Rel-family proteins,
which include RelA (p65), RelB, cRel, p50, and p52 in
mammalian cells [1]. RelA, RelB, and cRel subunits con-
tain a transactivation domain; p50 and p52 do not. These
subunits can form about a dozen different homo- and het-
erodimers. The best-characterized dimer is RelA/p50, also
known as the canonical NFκB. Rel family proteins have a
nuclear localization sequence (NLS) that permits their
translocation to the nucleus upon activation, where they
bind specific DNA sequences. The consensus bound by
canonical NFκB is typically represented by GGGRN-
NYYCC; other dimers have slightly different preferences
[2]. NFκB activation is transient in most scenarios and ter-
minated through the interaction between NFκB and the
inhibitory κB proteins (IκBs) and also through degrada-
tion by proteasomal activity in the nucleus [3]. IκBs can
mask the NLS of Rel proteins, and one of them (IκBα) has
a nuclear export sequence (NES) through which the
NFκB/IκBα complex is efficiently shuttled back to cytosol,
restoring the inactive state. NFκB activation typically
results from the breakdown of IκB proteins, an event
requiring multiple steps. Once a stimulus activates the
pathway, IκB kinases IKK1, IKK2, and IKK3 (the last is a
scaffolding protein) are activated, phosphorylating IκBs
[4]. Phosphorylated IκBs are degraded through the ubiq-
uitin/proteasome pathway. The degradation of IκBs liber-
ates NFκB and completes the activation cycle.
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Despite the similarities between Rel family members, spe-
cific components of the NFκB system play unique and
nonredundant roles [5,6]. One aspect of this specificity is
the preference of various dimers for different DNA
sequences [2]. There is also specificity in the stimuli and
mechanisms of activation. Tumor necrosis factor-α
(TNFα) and other activators of canonical NFκB signal
through IKK2. Lymphotoxin-α (a.k.a., "TNFβ") and CD40
ligand, on the other hand, induce the noncanonical path-
way via IKK1. IKK2 and canonical NFκB orchestrate
inflammation and a few other immune responses; they
also promote viability through the induction of several
anti-apoptosis genes [7-9]. IKK1 appears to be involved in
feedback inhibition of inflammation and contributes crit-
ically to development, with particular importance for
limb formation [10,11]. The noncanonical pathway uti-
lizes p100 (the precursor of p52) to mask the NLS of RelB,
excluding RelB/p100 from the nucleus without involve-
ment of a canonical IκB. Inactive RelB/p100 is converted
to active RelB/p52 by IKK1 and NFκB-inducing kinase
(NIK). Activated NIK preferentially phosphorylates IKK1
rather than IKK2, and activated IKK1 subsequently phos-
phorylates p100, which is then partially degraded to p52
through a ubiquitin-dependent mechanism. The resulting
RelB/p52 heterodimer constitutes active, noncanonical
NFκB.
NFκB activation in neurons? The case of 
glutamate
Glutamate is the major excitatory neurotransmitter in the
central nervous system (CNS), but it also exhibits toxicity
to most types of neurons. This excitotoxicity has been
implicated in many disease states [12], and NFκB has
complex roles in cellular viability and death [2]. There-
fore, elucidation of the potential interactions between
glutamate and NFκB is extremely important for under-
standing both normal and pathological brain functions.
Although NFκB activation is transient in all other systems,
it was initially reported to be constitutively active in corti-
cal neurons [13]. Shortly thereafter, that laboratory and
others reported that NFκB activity was activated after
glutamate treatment in cerebellar granule cell cultures
[14,15]. But the neuronal population in cerebellar granule
cell cultures cannot be enriched with mitotic inhibitors
[16,17]; so these results, obtained from cultures main-
tained in the presence of serum, raise the question of
whether the detected NFκB activity was truly from neu-
rons or from contaminating glia.
Because of our interest in both glutamatergic stimuli and
CNS transcriptional regulation, we made extensive
attempts to reproduce the activation of NFκB by gluta-
mate. These efforts have routinely utilized a rat cerebral
culture system [see Additional file 1] that is almost com-
pletely devoid of nonneuronal cell types. Using cell type-
specific immunocytochemistry, we determined that
mitotic inhibitors were not sufficient for producing glia-
free cultures of neurons; nor could a serum-free medium
alone achieve this goal. By using a mitotic inhibitor
together with serum-free medium we found we could
restrict glial contamination to less than one percent of
cells. Mitotic inhibitors are rather stressful to the neurons
themselves; and the most commonly used, cytosine arab-
inoside (AraC), has been reported to either stimulate [18]
or inhibit [19] NFκB itself. Therefore, we employed a tran-
sient AraC treatment, including it only in the first four
days in culture.
Many of the original reports of NFκB activation in neu-
rons were based on nuclear translocation of the transcrip-
tion factor as an endpoint. We tested this parameter in our
highly enriched cortical neuron cultures. Cells treated
with glutamate and then lysed and separated into a
cytosolic fraction (supernatant) and a nuclear fraction
(whole nuclear pellet sonicated) for analysis by western
blotting (note: this is different from the nuclear extract
used in EMSA, which only includes the salt-extractable
components). Glutamate was indeed found to evoke
nuclear translocation of RelA under these conditions (Fig-
ure 1). This is consistent with previous findings we
obtained with immunocytochemistry [20]. Translocation
of RelA-containing NFκB complexes is typically depend-
ent upon degradation of an IκB, so we assessed the levels
of IκBα in whole-cell lysates obtained after an identical
glutamate treatment. No significant levels of other IκB
proteins can be detected in cultured cortical neurons,
although multiple antibodies have been tested for each.
Interestingly, only a small reduction of IκBα levels could
be observed in neurons (Figure 1). This is particularly
apparent when compared to the nearly complete loss of
IκBα we observed in astrocytes treated with TNFα (Figure
1).
Nuclear translocation is necessary but not sufficient for
NFκB activation of transcription. Numerous circum-
stances have been documented in which NFκB moves to
the nucleus without effecting transactivation [21-29]. We
began to assay pure neuronal cultures by EMSA and found
that NFκB activity was undetectable by this measure after
glutamate treatment [30]. Many attempts have been made
subsequently, and we have broadened our tests of NFκB
activity to include transcriptional activation, as well. No
NFκB activity has been detected in glutamate-treated neu-
rons examined by EMSA, reporter-gene transfection, or a
stably integrated reporter transgene [2,20,30-32].
One possible explanation for discrepancies between our
findings and those of others is the composition of our cell
cultures. We tested the potential contributions of glia by
comparing our essentially glia-free neuronal cultures to
neuron-glia cocultures generated by the inclusion of serum.Journal of Neuroinflammation 2009, 6:16 http://www.jneuroinflammation.com/content/6/1/16
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These experiments consistently showed NFκB activation
the cocultures [2,20,30,31]. To determine the cell type con-
tributing this NFκB activity, we made use of a transwell coc-
ulture model that permitted us to physically separate
neurons from glia after glutamate treatment [31]. In this
format, we found that NFκB activity could not be induced
by glutamate in pure cultures of either  neurons or glia
alone. However, transwell cultures in which glia and neu-
rons were together for two days showed NFκB induction in
the glia but not in the neurons. One hypothesis to explain
these results is that glutamate-stimulated neurons release a
soluble factor that induces NFκB in glia. Alternatively, neu-
rons may chronically release a factor that alters the acute
responses of glial NFκB to glutamate. This latter idea is con-
sistent with our data: glutamate was incapable of inducing
NFκB in glia if they were placed with neurons only imme-
diately before glutamate stimulation. This result also dem-
onstrates that glia can be the source of NFκB in cocultures
even though pure astrocyte cultures do not show a response
to glutamate themselves; e.g., Guerrini et al. (1995) [15].
The above studies with glutamate and other stimuli were
largely conducted in cell culture. While this approach has
limitations, its contributions to our understanding of neu-
ronal transcription are important because it is technically
impossible to precisely determine both the location and
activity level of a transcription factor in vivo. The best strat-
egy for doing so involves making an animal transgenic for
a  β-galactosidase reporter gene driven by a promoter
responsive to the transcription factor of interest. Although
β-gal histochemistry is not exquisitely quantitative, it
nonetheless reports whether there has been some level of
transcription. Two such transgenic models suggest that
NFκB is constitutively active in neurons [33,34]. Bhakar et
al. [33] reported that constitutive NFκB activity could be
detected by the κB/β-gal reporter transgene, and this activ-
ity was required for survival of neurons. However, electro-
phoretic mobility shift assays (EMSA) conducted by the
authors failed to demonstrate DNA-binding activity for
NFκB (personal communication), which raises the possi-
bility that the basal activity of this κB/β-gal reporter is
driven by other κB-binding factor(s), such as Sp-factors
(below). In addition, the transgene integration site in the
genome might be critical for this reporter activity, and
those circumstances remain undetermined. Nevertheless,
no NFκB activity could be evoked by glutamate in these
transgenic neurons [2]. In the transgenic system devel-
oped by Fridmacher et al. [34], the reporter gene was
driven by the p105 (p50 precursor) promoter. This pro-
moter was selected for its NFκB-responsiveness, but Sp1-
related factors are also involved in regulation of this pro-
moter via κB and non-κB elements [35]. Furthermore, in
the initial report creating this p105-promoter/β-gal line, a
complex distinct from NFκB was shown to prominently
bind this promoter in EMSA [36]. It is now clear that this
constitutive κB-binding activity results from Sp1-related
factors [32]. Induction of an IκBα super-repressor inhib-
ited expression of the p105-promoter/β-gal reporter, but
IκBα also inhibits activity of Sp1-related factors [37], a
phenomenon that will become further relevant in discus-
sions below. Fridmacher et al. found that induction of the
IκBα super-repressor had no effect on neuronal survival
under basal conditions, contradicting the results from the
transgenic model reported by Bhakar et al. Fridmacher et
al. did not identify NFκB in neurons by EMSA or other
immunological methods.
RelA nuclear translocation in neurons after glutamate treatment Figure 1
RelA nuclear translocation in neurons after glutamate treatment. Nearly pure neocortical neurons were treated 
with glutamate (50 μM) for the indicated times and cells were harvested for fractionation (Cyto.: cytosolic fraction; Nuc.: 
nuclear fraction); these were probed by western blot for RelA. Whole-cell lysates were also prepared from either astrocyte or 
neuron cultures; these were probed by western blot for IκBα (Whole: neuron whole cell lysate). TNFα was applied to the 
astrocytes at 100 ng/ml for the indicated times (min).Journal of Neuroinflammation 2009, 6:16 http://www.jneuroinflammation.com/content/6/1/16
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We have further analyzed in vitro neurons from the trans-
genic line developed by Bhakar et al. [33]. The main objec-
tive was to explore the possibility that pure neuronal
cultures are altered in their handling of NFκB due to the
absence of a physical interaction with glia. To test this idea,
we cultured neurons from the κB/β-gal reporter line with
wild-type glia so that typical neuron-glia interactions could
take place, while the reporting of NFκB activity would be
specific to the neurons in the coculture. Wild-type astro-
cytes were first plated and grown to confluency, and then
E17 transgenic (κB/β-gal) cortical cells were added one
week prior to treatment. The pre-plated wild-type astrocytes
suppressed growth of transgenic glia but promoted survival
of the κB/β-gal neurons, as histochemistry showed no
astrocytes positive for β-gal. These cocultures were com-
pared to cultures of κB/β-gal neurons alone. Two treatment
paradigms were tested: 1) a transient exposure to glutamate
(10 min) followed by a 6- to 24-hour chase period, or 2)
continuous exposure to glutamate for 6 to 24 hours (Figure
2). Once again, neuronally localized NFκB activity could
not be induced by glutamate. Indeed, basal β-gal levels
were suppressed by glutamate exposure, an effect that was
partially suppressed in the presence of glia, presumably due
to the ability of astrocytes to metabolize glutamate. This
negative effect of glutamate on κB-dependent transcription
is consistent with copious EMSA data showing that gluta-
mate reduces the levels of κB-binding Sp1-related factors in
neurons (below).
Others have confirmed a similar degree of recalcitrance of
NFκB in CNS neurons [38,39]. But contradictory findings
have been reported, as well. Most notably, Kaltschmidt
and Kaltschmidt [40] provided immunocytochemical
data indicating that a five-minute exposure to kainate trig-
gered an increase in "active" RelA immunogenicity (some
of which was nuclear) in neurons an hour later. This
apparent activation did not occur if a coverslip plated with
astrocytes was placed over the neurons after the stimulus.
Astrocytes exhibit high rates of glutamate uptake and ami-
nation; thus, they would be expected to attenuate events
dependent upon glutamate receptors if the agonist was
glutamate itself. Indeed, we found that astrocytes inhib-
ited the glutamate-evoked diminution of transactivation
in κB/β-gal neurons (Figure 2). However, kainate is not a
substrate for glutamate transporters, and no coverslip-
borne astrocytes were present when Kaltschmidt and Kalt-
schmidt applied kainate to their neurons. Their results
thus indicate some influence of astrocytes on neuronal
RelA after glutamate receptor activation had ceased. This
does not appear to be the result of a soluble factor, as the
control neurons received astrocyte-conditioned medium.
Nor does it appear to depend on cell-cell contact, as the
astrocytes on the coverslip were physically separated from
the neurons. Notably, the "neuronal" cultures (lacking the
astrocyte coverslip) in these experiments were plated in
the presence of 10% serum and thus contained approxi-
mately 10% glia [40]. It is somewhat surprising that this
more intimate association of glia with the neurons was
insignificant compared to that provided by the coverslip's
astrocytes. In the end, the results of this study remain
unexplained, irrespective of their relationship to our
results with cocultures. Moreover, Kaltschmidt and Kalt-
schmidt failed to demonstrate DNA binding or transcrip-
tional activation by NFκB in their cocultures.
Glutamate is unable to activate neuronal NFκB in mixed cell  cultures Figure 2
Glutamate is unable to activate neuronal NFκB in 
mixed cell cultures. Neocortical neurons from κB/β-gal 
transgenic mice were either plated on the top of wild-type 
astrocytes ("+glia") or retained as nearly pure neuronal cul-
tures ("-glia"). A. Glutamate was applied at 50 μM for 10 min, 
then chased for the times indicated (h). B. Glutamate was 
applied at 20 μM continuously for the times indicated (h). β-
gal activity was determined by a luminescent assay. Values 
represent activity relative to untreated cultures ± SEM in 
quadruplicate cultures. ANOVA followed by Scheffe post-
hoc test showed significance between control and each treat-
ment, and between the "+glia" and "-glia" in all comparisons 
except the 6 h timepoint in A. (p < 0.02).Journal of Neuroinflammation 2009, 6:16 http://www.jneuroinflammation.com/content/6/1/16
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Although our original focus was to test the reported induc-
tion of NFκB by glutamatergic agonism, we have also
examined other stimuli. To date, we have failed to detect
appreciable NFκB activity in neurons treated with TNFα,
nerve growth factor, brain-derived neurotrophic factor,
cholinergic or adrenergic agonists, cytoskeletal drugs, or
oxidants (e.g., hydrogen peroxide). Many of these stimuli
generated detectable NFκB activity when as few as 5% of
the cells in the culture were glia.
Together, these data and their caveats provide the conclu-
sion that no convincing evidence supports the full activa-
tion of NFκB in neurons, although the initial stages up
through nuclear translocation have been detected by our-
selves and others (Figure 1; see also Ref. [20]). Most of our
work has been conducted with cultured cortical neurons
equivalent to post-natal days 2–5, and it is possible that
they fundamentally differ from cortical neurons in situ in
the adult. However, such cultured neurons are post-
mitotic by virtue of our transient AraC treatment, and they
exhibit mature responses to glutamate [41]. Thus, they
can be said to differ more from the nonneuronal cells that
do exhibit NFκB activity than from the mature neurons of
adult brain. It is also meaningful that the NFκB function
does not appear to be required for normal development
or function of the CNS. These parameters are normal in
the various mouse lines with genetic ablation of key com-
ponents of the NFκB pathway, most of which appear to
have unique, nonredundant roles [42]. These data
strongly suggest that either NFκB is passively defective in
neurons or there exist special circumstances actively
blocking glutamate-triggered NFκB activity. Either case
would be consistent with the notion that the CNS, as a
partially immunoprivileged site, requires the silencing of
NFκB in neurons. In all, these issues stimulate interest in
potential mechanisms that might be responsible for
unique regulation of NFκB in neurons.
Dissecting the neuronal NFκB pathway
Cloning of RelA and IκBs from neurons
To test if the NFκB pathway is intact in neurons, it would
be reasonable to start with RelA. Several RelA splicing var-
iants have been reported [43-47]. One of them (p65Δ) is
particularly interesting because this RelA splicing variant
lacks nine residues critical for DNA-binding [44]. This
alternative splicing naturally occurs in human and mouse
[45]. If this were the sole splice variant expressed in neu-
NFκB activity in neurons cannot be evoked by supplementing  key components of its pathway Figure 4
NFκB activity in neurons cannot be evoked by sup-
plementing key components of its pathway. IKK1, 
IKK2, IKK3, NIK, β-TrCP1, and TRAF2 were transfected 
either alone or in combination as indicated to test NFκB 
activity in neocortical neurons by reporter assays with a κB-
driven firefly luciferase construct. Some transfection condi-
tions were also further treated with rat TNFα (1–100 ng/ml). 
Rat RelA transfection served as a positive control. After 24 
h, firefly luciferase activities were determined relative to 
Renilla luciferase reference. Values reflect the mean ± SEM of 
triplicate cultures. Except RelA transfection, no condition 
created a significant change compared to control.
Differential levels of mRNA for key components of the NFκB  pathway in neurons versus glia Figure 3
Differential levels of mRNA for key components of 
the NFκB pathway in neurons versus glia. RNA was 
harvested from rat primary neocortical neurons and astro-
cytes. Semiquantitive RT-PCR was performed on equal 
amounts of total mRNA to survey expression of genes in the 
NFκB pathway, housekeeping genes, and Sp-family factors 
[see Additional file 1]. Each lane represents one of four indi-
vidual cultures.Journal of Neuroinflammation 2009, 6:16 http://www.jneuroinflammation.com/content/6/1/16
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rons, this could explain the observed deficiency of NFκB
activity in neurons. However, the alternative splice-accep-
tor site present in human and mouse does not exist in the
rat genome. Therefore, a p65Δ  would be extremely
unlikely in rat neurons. Moreover, we cloned RelA cDNA
from cortical neurons (accession # AY307375) and found
that all the serine residues potentially critical for RelA
function are present. Furthermore, when it was transfected
in neurons, rat neuronal RelA showed high activity (see
below). These data indicate that there is no inherent
defect in rat neuronal RelA. These data also indicate that
RelA overexpressed from a transgene can behave differ-
ently from its endogenous counterpart, presumably
because the transfected RelA is expressed at levels high
enough to overwhelm some intrinsic inhibitory process.
In addition, these data suggest that caution should be
used in interpreting data obtained from NFκB transfection
studies (e.g., Ref. [48]).
Glutamate treatment triggers a relatively small reduction
of IκBα proteins, suggesting that the unresponsiveness of
neuronal NFκB might result from a defect in IκB degrada-
tion. IκBα degradation is triggered by phosphorylation of
two serine residues, an event which signals degradation
through a ubiquitin-dependent pathway involving β-TrCP
[49]. Either an alteration of those critical serines or a defi-
ciency in β-TrCP-dependent ubiquitin could result in
insufficient IκB degradation and low NFκB activity. We
cloned IκBα and IκBβ genes from rat neurons, and their
sequences showed no mutations compared to those pub-
lished (data not shown). In addition, expression of a β-
TrCP transgene did not permit induction of a κB-driven
luciferase reporter-gene construct (below). Therefore,
both RelA and major IκB genes appear normal in neurons.
We extended our scope to other players in the pathway in
a quest for potential differences between CNS neurons
and other cell types.
Profiling components of the NFκB pathway in neurons
RT-PCR was used to probe the mRNA expression levels of
the major components of NFκB pathway. After optimiz-
ing PCR conditions, unequivocal products for each of
these genes were obtained from glia. Then, identical con-
ditions were used to compare glia and neuron samples. In
each case, more than one pair of primers was used, and
consistent results were observed for the same gene [see
Additional file 2]. The results from one set of primers for
each gene are shown (Figure 3). The genes tested included
RelA, IκBα, IκBβ, IKK1, IKK2, IKK3/NEMO, and NIK.
Controls included three house-keeping genes: β-actin,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
cyclophilin. For reasons explained below, we also exam-
ined the Sp-factors Sp1, Sp3, and Sp4. Generally, the
mRNA level of every component in the NFκB pathway was
expressed significantly lower in neurons than in astrocytes
(p < 0.05 for each gene, astrocytes vs. neurons). β-actin
was also expressed at a lower level in neurons (p < 0.05).
However, GAPDH, cyclophilin, and Sp3 mRNA levels
were almost equivalent in neurons and astrocytes; Sp4
mRNA levels were significantly higher in neurons than in
astrocytes (p  < 0.05) (see also Ref. [50] for Sp-factor
expression). Therefore, these PCR results appear to reflect
a significantly lower expression in neurons than in glia for
every component of the NFκB pathway.
Reporter assays for complementing the NFκB pathway in 
neurons
Another intriguing fact is that Sp1 protein is nearly absent
in neurons, although Sp1 mRNA can be detected [51].
Upstream components of NFκB pathway cannot boost exog- enous RelA activity in neurons Figure 5
Upstream components of NFκB pathway cannot 
boost exogenous RelA activity in neurons. Primary 
neocortical neurons were transfected with a κB-driven firefly 
luciferase reporter, along with RelA and other key factors in 
the NFκB pathway. (The dose of RelA plasmid was selected 
to be intermediate with respect to the maximal level of the 
assay's dynamic range.) In some conditions, cells were 
treated with rat TNFα (10 ng/ml) after transfection. Relative 
luciferase activity from RelA (100 ng) transfection was 111.05 
± 8.9 (mean ± SEM) (not shown). All plasmids were 100 ng/
well, except those labeled otherwise. After 24 h, firefly luci-
ferase activities were determined relative to Renilla luciferase 
reference. Values reflect the mean ± SEM of triplicate cul-
tures. *p < 0.05 (t-test; other significant differences are not 
labeled).Journal of Neuroinflammation 2009, 6:16 http://www.jneuroinflammation.com/content/6/1/16
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Similarly, the deficiency of NFκB mRNAs in neurons may
actually under-represent a more profound deficiency in
protein levels. This issue was addressed through a recon-
stitution approach using expression of a κB-driven luci-
ferase reporter-gene as the endpoint. It should be noted
that the κB element in our luciferase reporter excludes
nucleotides that allow binding by Sp-factors and RBP-Jκ
(below), thus rendering it specific for NFκB. Several com-
ponents of the NFκB pathway, including β-TrCP, were
overexpressed by transfection [see Additional file 1] to test
whether their expression would be permissive for the
induction of endogenous NFκB activity in neurons. Over-
expression of a TNF receptor association factor (TRAF) is
sufficient to activate NFκB in many cell types [52]. How-
ever, neither TRAF2 (Figure 4) nor TRAF6 (not shown)
could activate NFκB in neurons, as measured by a cotrans-
fected κB-driven luciferase reporter. Indeed, none of the
constituents of the NFκB pathway was effective. Several
components were cotransfected in combination with one
another (Figure 4). Even so, NFκB activation was never
detected in any of these conditions except for one: the
overexpression of RelA. A low dose of RelA expression
plasmid was used to replace TRAF2 to repeat the experi-
ment. This modest level of exogenously supplied activity
could not be boosted further by cotransfection of any of
combination of IKKs (Figure 5). These findings suggest
that there are no passive functional deficiencies of major
components of the NFκB pathway in neurons.
Searching for mechanisms of NFκB repression
All of the requisite components of the NFκB system
appear to be expressed in forebrain neurons (Figure 3 and
data not shown). In addition, providing additional com-
ponents by transfection did not create a responsive system
in neurons. These findings are consistent with there being
an active repression of NFκB in forebrain neurons. To test
candidate mechanisms for this repression, we used the
following approaches:
1) Transcription coordinator p300 is important for
NFκB transactivity, and p300 might be competed out
by some other factors such as estrogen receptor [53] in
neurons. However, overexpression of p300 in neurons
with or without glutamate treatment did not increase
κB-driven reporter activity.
2) Acetylation has been reported to be important for
RelA function [54]. A triple mutation of RelA (K218/221/
310→R) completely incapable of being acetylated was
transfected into neurons. This RelA mutant possessed
activity as high as the wild-type RelA transgene, sug-
gesting that acetylation is not essential for RelA activity
in neurons.
3) Phosphorylation has been reported to be crucial for
RelA function in some scenarios. Many serine residues
have been identified as important: Ser529 [25], Ser536
[55], Ser337 [56], Ser205/Ser278/Ser281 [57], and Ser311
[58]. RelA cloned from rat cortical neurons did not
show mutations at any of the relevant serines (see
below). Moreover, these phosphorylation events affect
RelA's transactivation activity rather than its DNA-
binding activity, and neuronal NFκB seems to be defi-
cient in DNA-binding activity. Finally, we tested a
S281→G RelA mutant in reporter assays, and this
mutant functioned as well as the wild-type RelA trans-
gene. Therefore, it seems highly unlikely that phos-
phorylation of RelA is a critical determinant of NFκB
activity in neurons.
4) Transcription factor p53 has been reported to sup-
press NFκB activity [59]. However, we found that p53
ApoE declines with Sp1 during neuronal differentiation but is induced by glutamate Figure 6
ApoE declines with Sp1 during neuronal differentiation but is induced by glutamate. A. NTera2 cells were har-
vested undifferentiated (U) or after incubation as neurospheres in retinoic acid for 14 days (RA). Subsequent to RA treatment, 
additional cultures underwent selection by incubation with a cocktail of mitotic inhibitors (MI) for 7 days. Equal amounts of 
protein were resolved by SDS-PAGE, and the levels of ApoE, Sp1, and Sp4 were assessed by western blot analysis. B. Differen-
tiated NTera2 cells were untreated or treated with 20 μM glutamate for 20 h, then levels of ApoE and actin were assessed by 
western blot.Journal of Neuroinflammation 2009, 6:16 http://www.jneuroinflammation.com/content/6/1/16
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inhibitor pifithrin-α had no effect on NFκB reporter-
gene activity in neurons.
5) Another Rel-factor RelB has been shown to inhibit
RelA activity by disrupting its DNA binding [60].
However, when RelB was transfected into neurons, it
did not alter the activity of co-transfected RelA. More-
over, RelB expression levels are very low in neurons as
determined by several antibodies in western blot anal-
yses.
6) The progesterone receptor can be induced to bind
directly to NFκB and inhibit its activity, and progester-
one is a component of the medium we routinely use
for neuronal cultures: Neurobasal with B27 supple-
ment. To control for progesterone and any unknown
components of Neurobasal/B27, we tested for NFκB in
neurons cultured in minimal essential medium con-
taining N2 supplements with or without progesterone
[20]. Again, reporter-gene assays and EMSAs showed
no basal nor induced NFκB activity in neurons.
Binding of κB enhancers by Sp1-related factors
Specific protein-1 (Sp1) is the prototypical member of a
group of highly homologous zinc-finger transcription fac-
tors that includes Sp1 through -9 and the Krüppel-like fac-
tors (of which there are as many as 17 in humans)
[61,62]. Despite similarities in the zinc-finger domains
among the family, only Sp3 and Sp4 share the DNA bind-
ing sequence first identified with Sp1. Like most NFκB tar-
get sequences, the sites bound by these three Sp-factors are
GC-rich. We and others have reported specific, robust,
and functional binding of Sp1, -3, and -4 to a subset of
NFκB target sequences [32,63]. Indeed, binding by the lat-
ter two accounts for more than 95% of the binding to cer-
tain κB elements in neurons.
In our initial examination of Sp-factors in neurons, we
assumed that reports of Sp1 ubiquity in the CNS were
accurate. This prejudice, combined with antibodies that
were at least partially cross-reactive with multiple Sp-fam-
ily members, led us to conclude that it was indeed Sp1
that was responsible for κB binding in EMSA with neuro-
nal extracts. Subsequently, we found that the presence of
Sp4 in mature neurons corresponds to a near absence of
Sp1 [51]. Immunofluorescence data obtained in our cul-
tures, as well as in the cortex of adult rats, reveals negligi-
ble colocalization of Sp1 with neuronal markers and clear
colocalization of Sp1 with the astrocyte marker glial fibril-
lary acidic protein (GFAP); the converse is true for Sp4.
We also assessed the expression of these proteins in cell
cultures highly enriched for neurons or glia, as well as in
glial and neuronal cell lines. Both western blot analysis
and RT-PCR analysis of mRNA indicate that Sp1 expres-
sion is much higher in glia than in neurons, and Sp4
shows the converse. Finally, we performed supershift
analyses in EMSA; Sp1 antibodies altered the mobility of
the Sp-factors only in glial cultures and Sp4 antibodies did
so only in neuronal cultures. By all these methods Sp3 was
found to be expressed at similar levels in both neuronal
and nonneuronal cells.
The replacement of Sp1 by Sp4 appears to have important
ramifications for gene expression. Sp1 is primarily a tran-
scriptional inducer, but Sp4 has often been connected to
transcriptional repression, particularly when expressed in
the presence of Sp3 [64,65]. Although others have shown
that Sp1 overexpression in neurons can have powerful
biological effects, our data would argue that the natural
situation is replacement of this transcriptional inducer by
the repressor-competent Sp4. While Sp4 can act as a tran-
scriptional activator [66], it appears incapable of doing so
in the presence of Sp3 [32,64], which is abundant in cor-
Induction of neuronal expression of cyclin D1 in βAPP-defi- cient mice Figure 7
Induction of neuronal expression of cyclin D1 in 
βAPP-deficient mice. Brain sections from wild-type 
("WT") and βAPP-knockout ("APP-KO") mice were sub-
jected to immunofluorescence detection of cyclin D1 
(green). The sections were counterstained with DAPI to vis-
ualize nuclei (blue). Representative images are shown. The 
pixel intensity of specific staining was randomly sampled in 
the CA1 and dentate cell body layer. The mean values and 
standard errors are shown in graphically. Statistical compari-
son between the two genotypes by t-test indicated p < 0.05 
(n = 4) in each hippocampal region.Journal of Neuroinflammation 2009, 6:16 http://www.jneuroinflammation.com/content/6/1/16
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tical neurons [51]. Alternatively, Sp4 may be primarily a
stimulatory factor at "Sp1" binding sites and inhibitory at
κB elements. Further studies are required to explore these
interesting possibilities.
Sp1 and Sp4 dynamics may have important effects on the
terminal differentiation of post-mitotic neurons. Indeed,
Sp1 plays key roles in mitosis [67]. It is responsible for
inducing expression of key cell-cycle regulatory genes such
as cdc25C [68], cyclin B1 [69], cyclin D1 [70], cyclin E1
[71], and thymidine kinase [72]; these genes may be
much less responsive to Sp4, a trait already demonstrated
for thymidine kinase [72]. Sp1 is phosphorylated by cyc-
lin-dependent kinase 2 (Cdk2) at Ser59 during the S-phase
of the cell cycle, and this results in transactivation of dihy-
drofolate reductase (DHFR) [73], an essential event in the
production of thymidine for DNA synthesis. Sp1 is also
associated physically with cyclin A and cyclin E1 during S-
phase [74]. Reductions in the level or activity of Sp1 can
block mitosis [75,76]. We have noted a dramatic suppres-
sion of Sp1 expression after differentiation of NTera2 cells
into neurons (Figure 6A).
Sp4 expression, already apparent in undifferentiated
NTera2 cells [51], appears to increase slightly during the
differentiation process (Figure 6A). It is possible that
induction of Sp4 is an important event in readying neural
stem cells for differentiation down the neuronal path. The
functional implications of the Sp1:Sp4 ratio may not be
limited to cell cycle regulation. Apolipoprotein E (ApoE)
expression is normally limited to astrocytes and not neu-
rons [76], and the ApoE promoter is responsive to Sp1
[77]. We found that during differentiation of NTera2 cells
[see Additional file 1], ApoE levels decreased proportion-
ally with Sp1 while Sp4 remained abundant (Figure 6A).
This is consistent with a prior demonstration that ApoE is
squelched during differentiation of NTera2 cells [78] and
may indicate that Sp4 exerts a transcriptional repression at
the Sp1 element in the ApoE promoter.
Neuronal expression of ApoE can be induced by excito-
toxic stress [79,80], and we found that glutamate-medi-
ated excitotoxic stress results in an increase in ApoE levels
in differentiated NTera2 cells (Figure 6B; see also Ref.
[81]). The induction of neuronal ApoE expression by
glutamate and other excitotoxic agents may involve
release from the repressive influence of Sp4. The DNA-
binding activity attributable to Sp3 and Sp4 is diminished
by glutamate treatment [30-32,51]. This phenomenon
occurs rapidly – within 30 min of treatment of CNS neu-
rons destined to die 20–24 hours later [30,51]. We deter-
mined that this depletion is dependent on calcium influx
through NMDA receptors and correlates with the appear-
ance of smaller DNA-binding proteins. The levels of intact
Sp3 and Sp4 also decrease with similar kinetics and phar-
macology in western blot analysis [51]. It was eventually
determined that activation of the calcium-dependent pro-
tease calpain is responsible for the loss of these proteins
(and their conversion to smaller intermediates that retain
DNA-binding activity). Rapid loss of Sp-factors is also
associated with delayed toxicity caused by oxidative stress
[30], though this apparently occurs through a calpain-
independent process because it does not generate the
same proteolytic products as does glutamate (data not
shown). It is not known whether the early loss of Sp3 and
Sp4 contributes to the cell death occurring later; it is pos-
sible that there are compensatory benefits resulting from
attenuation of the levels and activities of these transcrip-
tion factors. The latter idea is given some support by the
finding that neuronal Sp-factors have an inhibitory influ-
ence on transcription via a regulatory element in the Sod2
gene (below). Thus, their degradation under conditions of
stress could be permissive for the elevation of a protective
antioxidant enzyme.
Schematic for the roles of Sp1 and Sp4 in neuronal differentiation and degeneration Figure 8
Schematic for the roles of Sp1 and Sp4 in neuronal differentiation and degeneration. Immature neuroblasts appear 
to similar levels of Sp1 and Sp4, perhaps competing for regulatory control of genes not strongly related to differentiated neu-
ronal function. After differentiation, mature neurons have much lower levels of Sp1; Sp4 competitively inhibits DNA binding 
and exerts transcriptional repression on genes related to mitosis and other genes inappropriate for neurons, such as ApoE. 
Upon excessive stimulation of glutamate receptors, a large calcium influx activates calpain, which digests Sp4. This may relieve 
the transcriptional repression of mitotic genes, permitting their inappropriate expression in terminally differentiated neurons; 
the latter appears sufficient to trigger apoptosis.Journal of Neuroinflammation 2009, 6:16 http://www.jneuroinflammation.com/content/6/1/16
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Cell-type specificity of a κB element: regulation 
of the Sod2 gene
To test the effects of Sp-factors on κB-driven genes in neu-
rons, we analyzed several κB sequences predicted to bind
Sp-factors [50]. One of these lies in the gene for superox-
ide dismutase-2 (Mn-SOD), which has an intronic
enhancer element previously shown to be regulated by
NFκB in nonneuronal cells lying within rat Sod2 intron 2
(RSI) [82,83]. We confirmed that the RSI κB element was
bound by NFκB using EMSA. In nuclear extracts from
TNFα-treated astrocytes, three major complexes were
detected [50]. Through supershift assays with an array of
antibodies against Rel-factors and Sp-family proteins, the
three complexes were identified as p50/p50, p65/p50,
and Sp1 comigrating with Sp3. On the other hand, there
was only one complex from neuronal nuclear extracts,
and it was identified as Sp3 comigrating with Sp4 [50].
These data indicated that the proteins capable of binding
the Sod2-κB site differed dramatically between astrocytes
and neurons; notably, binding by NFκB and Sp1 was
absent in neurons.
To test the functional consequences of distinct Sod2-κB-
binding proteins, a luciferase reporter plasmid was con-
structed containing 500 bp of the RSI. Again, no activation
could be detected in neurons after glutamate treatment
[50]. Furthermore, Sp3 and Sp4 suppressed the promoter
activity through the κB site in neurons, because expression
was elevated by either point mutation of the κB site or
depletion of available Sp-family proteins with decoy oli-
gonucleotides. As predicted by the EMSA data, IκBα
cotransfection had no effect in neurons. RelA cotransfec-
tion significantly enhanced the reporter activity, which
could be completely blocked by IκBα coexpression. The
activity of the intronic promoter was high in astrocytes (at
least partially due to the fact that glia are activated by
transfection itself) and was drastically inhibited by Sp1-
decoy oligonucleotides or IκBα; activity was completely
abolished by combination of the two [50]. Together, these
data showed that Sp-factors (Sp3 and Sp4) are the major
neuronal κB-binding factors and that they suppress tran-
scriptional activity by interacting with the intronic κB site
in neurons. On the contrary, glial Sp-factors (Sp1 and
Sp3) result in activation that can synergize with that pro-
duced by NFκB through the same κB site. A tandem κB-
element has been identified in the promoter for βAPP
[84]. Mutation of these two κB sites in the βAPP promoter
(3.8 kb) did not change its activity in neurons, further
demonstrating that NFκB is not involved in regulating κB
elements in neurons under basal conditions.
Significance for neuroinflammatory disease
Because of its importance for expression of cytokines and
other factors related to inflammation, NFκB has been tar-
geted for inhibition by some therapeutic strategies. The
actions of certain pharmacotherapeutic agents such as
aspirin are thought to include inhibition of NFκB, and
this may be an effect of more recently developed drugs
such as agonists of peroxisome proliferator-activated
receptors (PPAR) [85,86]. Therapeutic objectives also
inspired the development of specific IKK inhibitors,
which has been a boon to research, as well. With the dis-
covery of anti-apoptotic actions of NFκB, some have sup-
posed that its inhibition might be dangerous to CNS
neurons [87]. While our findings do not rule out a contri-
bution of NFκB to neuronal survival under every condi-
tion, they do suggest that control of inflammation by
inhibition of NFκB will not cause significant levels of neu-
ronal cell death. Recently, it has been proposed that
homo- or heterodimers of c-Rel are neuroprotective
whereas p50/RelA is neurotoxic [88]. However, c-Rel-con-
taining species are activated via the canonical IKK2-
dependent pathway and are thus just as sensitive to sali-
cylates [89] (and other IKK inhibitors). Salicylates and
IKK inhibitors are associated with positive outcomes in a
variety of neurotoxicological models [90-94], indicating
that neurons probably do not depend upon tonic NFκB
activity.
As a specific neuroinflammatory condition, Alzheimer's
disease might hold relevance for the unique expression
and regulation of transcription factors we have found in
neurons. We recently conducted an analysis of βAPP
expression in normal aging and Alzheimer's disease [81].
These studies documented a glutamate-triggered induc-
tion of βAPP expression that is dependent upon the prod-
uct of the ε3 allele of apolipoprotein E (ApoE3).
(Possession of the major alternative allele in humans,
ApoE4, is associated with a dramatically increased risk for
Alzheimer's disease.) Moreover, our findings indicated
that this glutamate→ApoE3→βAPP axis becomes uncou-
pled in the early stages of Alzheimer pathogenesis. ApoE
levels continue to rise with advancing Alzheimer pathol-
ogy, but de novo expression of βAPP in neuronal somata is
dramatically depleted. To test the consequences of this
loss of βAPP, we examined βAPP-knockout mice [95].
Neurons in the brains of these mice showed elevated
expression of cyclins D1 (Figure 7) and E1 (not shown),
which have promoters that are responsive to Sp1. Such
ectopic expression of cell cycle markers in post-mitotic
neurons is a curious component of pathology found in
Alzheimer's and other neurodegenerative conditions and
one that appears to trigger apoptosis [96]. It is possible
that this phenomenon involves derangement of the
Sp4:Sp1 ratio in stressed neurons.
In light of the information produced by our analysis of
Sp1-related factors, we propose a model with implications
for neurodegeneration such as that occurring in Alzhe-
imer's (Figure 8). The ApoE gene has an Sp-factor bindingJournal of Neuroinflammation 2009, 6:16 http://www.jneuroinflammation.com/content/6/1/16
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site in its promoter that permits induction by Sp1 in non-
neuronal cells [77], but ApoE is suppressed in neurons
[97]. We propose that this is a result of the Sp1→Sp4
switch during neuronal differentiation. Moreover, we pro-
pose that the induction of ApoE by glutamate we have
observed [81] results from a calpain-mediated degrada-
tion of Sp4, thus liberating ApoE from an Sp4-mediated
suppression. Finally, we propose that dysregulation of
normal aspects of neuronal differentiation in Alzheimer's,
perhaps brought about by loss of Sp4, leads to ectopic
expression of cell cycle proteins and neuronal cell death.
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